{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:04:44Z","timestamp":1775732684694,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.heliyon.2024.e38336","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T02:18:15Z","timestamp":1727662695000},"page":"e38336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Absence of platelet overactivation and thrombosis formation among patients with coronary atherosclerosis disease after vaccination against SARS-CoV-2"],"prefix":"10.1016","volume":"10","author":[{"given":"Huajie","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huibin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.heliyon.2024.e38336_bib1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3390\/vaccines11081347","article-title":"Exigency of plant-based vaccine against COVID-19 emergence as pandemic preparedness","volume":"11","author":"Chattopadhyay","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.heliyon.2024.e38336_bib2","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination","volume":"384","author":"Muir","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e38336_bib3","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e38336_bib4","article-title":"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study","volume":"373","author":"Pottegard","year":"2021","journal-title":"Bmj-Brit Med J"},{"key":"10.1016\/j.heliyon.2024.e38336_bib5","article-title":"Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study","volume":"374","author":"Hippisley-Cox","year":"2021","journal-title":"Bmj-Brit Med J"},{"key":"10.1016\/j.heliyon.2024.e38336_bib6","article-title":"Cerebral venous sinus thrombosis is not significantly linked to COVID-19 vaccines or non-COVID vaccines in a large multi-state health system","volume":"30","author":"Pawlowski","year":"2021","journal-title":"J. Stroke Cerebrovasc"},{"key":"10.1016\/j.heliyon.2024.e38336_bib7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12959-021-00340-4","article-title":"Thromboembolic and hemorrhagic risks after vaccination against SARS-CoV-2: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Uaprasert","year":"2021","journal-title":"Thromb. J."},{"key":"10.1016\/j.heliyon.2024.e38336_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1586\/14779072.2.4.535","article-title":"Platelet activation in myocardial ischemic syndromes","volume":"2","author":"Gurbel","year":"2004","journal-title":"Expert Rev Cardiovas"},{"key":"10.1016\/j.heliyon.2024.e38336_bib9","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/eurheartj\/ehaa388","article-title":"Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy","volume":"41","author":"Inciardi","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.heliyon.2024.e38336_bib10","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1038\/s41467-022-32547-y","article-title":"Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein","volume":"13","author":"Castro","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e38336_bib11","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1093\/eurheartj\/ehac034","article-title":"Galectin 3 enhances platelet aggregation and thrombosis via Dectin-1 activation: a translational study","volume":"43","author":"Chen","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.heliyon.2024.e38336_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","article-title":"PCSK9 (proprotein convertase subtilisin\/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36","volume":"143","author":"Qi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e38336_bib13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-020-00954-7","article-title":"SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e38336_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","article-title":"PCSK9 (proprotein convertase subtilisin\/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36","volume":"143","author":"Qi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e38336_bib15","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1007\/s12325-019-01032-2","article-title":"Association between residual platelet reactivity on clopidogrel treatment and severity of coronary atherosclerosis: intrinsic hypercoagulability as a mediator","volume":"36","author":"Zhao","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.heliyon.2024.e38336_bib16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jhep.2021.04.026","article-title":"Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study","volume":"75","author":"Wang","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e38336_bib17","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.scib.2021.07.033","article-title":"Inactivated SARS-CoV-2 vaccine does not influence the profile of prothrombotic antibody nor increase the risk of thrombosis in a prospective Chinese cohort","volume":"66","author":"Liu","year":"2021","journal-title":"Sci. Bull."},{"key":"10.1016\/j.heliyon.2024.e38336_bib18","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"27","author":"Simpson","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e38336_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvac068","article-title":"Association between BNT162b2 or CoronaVac COVID-19 vaccines and major adverse cardiovascular events among individuals with cardiovascular disease","author":"Ye","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.heliyon.2024.e38336_bib20","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1016\/S2666-7568(22)00125-8","article-title":"Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series","volume":"3","author":"Wan","year":"2022","journal-title":"Lancet Health Longev"},{"key":"10.1016\/j.heliyon.2024.e38336_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.779453","article-title":"Inflammation and platelet activation after COVID-19 vaccines - possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis","volume":"12","author":"Ostrowski","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e38336_bib22","article-title":"Platelet surface protein expression and reactivity upon TRAP stimulation after BNT162b2 vaccination","author":"Klug","year":"2021","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.heliyon.2024.e38336_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.967926","article-title":"Thrombotic events with or without thrombocytopenia in recipients of adenovirus-based COVID-19 vaccines","volume":"9","author":"Cari","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.heliyon.2024.e38336_bib24","series-title":"AstraZeneca's COVID-19 Vaccine: EMAFinds Possible Link to Very Rare Cases of Unusual Blood Clots with Low Blood Platelets","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e38336_bib25","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e38336_bib26","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e38336_bib27","series-title":"Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e38336_bib28","article-title":"US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination","author":"See","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38336_bib29","first-page":"478","article-title":"Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration","volume":"140","author":"Nicolai","year":"2022","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/j.heliyon.2024.e38336_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood.2021012217","article-title":"Frequency of positive anti-PF4\/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2","volume":"138","author":"Thiele","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e38336_bib31","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2010-08-301424","article-title":"Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia","volume":"117","author":"Krauel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e38336_bib32","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood-2013-11-540781","article-title":"B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia","volume":"123","author":"Zheng","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e38336_bib33","article-title":"Assessing clinically meaningful hypercoagulability after COVID-19 vaccination: a longitudinal study","author":"Campello","year":"2022","journal-title":"Thromb. Haemostasis"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38336_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13643-024-02597-y","article-title":"COVID-19 antibody responses in individuals with natural immunity and with vaccination-induced immunity: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2024","journal-title":"Syst. Rev."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38336_bib35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.vaccine.2023.12.021","article-title":"Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination","volume":"42","author":"Zhan","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2024.e38336_bib36","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024143678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024143678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T10:17:20Z","timestamp":1775729840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024143678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":36,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2405844024143678"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38336","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Absence of platelet overactivation and thrombosis formation among patients with coronary atherosclerosis disease after vaccination against SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e38336"}}